318 related articles for article (PubMed ID: 21314637)
1. Platelet function and antiplatelet therapy in cardiovascular disease: implications of genetic polymorphisms.
Shanker J; Gasparyan AY; Kitas GD; Kakkar VV
Curr Vasc Pharmacol; 2011 Jul; 9(4):479-89. PubMed ID: 21314637
[TBL] [Abstract][Full Text] [Related]
2. Combination antiplatelet treatment in coronary artery disease patients: A necessary evil or an overzealous practice?
Alexopoulos D; Katogiannis K; Sfantou D; Lekakis J
Platelets; 2018 May; 29(3):228-237. PubMed ID: 29022423
[TBL] [Abstract][Full Text] [Related]
3. Clinical use of clopidogrel.
Sarafoff N; Byrne RA; Sibbing D
Curr Pharm Des; 2012; 18(33):5224-39. PubMed ID: 22724411
[TBL] [Abstract][Full Text] [Related]
4. The genetics of antiplatelet drug resistance.
Feher G; Feher A; Pusch G; Lupkovics G; Szapary L; Papp E
Clin Genet; 2009 Jan; 75(1):1-18. PubMed ID: 19067731
[TBL] [Abstract][Full Text] [Related]
5. Lack of association between the 807 C/T polymorphism of glycoprotein Ia gene and post-treatment platelet reactivity after aspirin and clopidogrel in patients with acute coronary syndrome.
Cuisset T; Frere C; Quilici J; Morange PE; Saut N; Romero-Barra M; Camoin L; Lambert M; Juhan-Vague I; Bonnet JL; Alessi MC
Thromb Haemost; 2007 Feb; 97(2):212-7. PubMed ID: 17264949
[TBL] [Abstract][Full Text] [Related]
6. The Impact of CYP2C19 Loss-of-Function Polymorphisms, Clinical, and Demographic Variables on Platelet Response to Clopidogrel Evaluated Using Impedance Aggregometry.
Mărginean A; Bănescu C; Moldovan V; Scridon A; Mărginean M; Bălaşa R; Maier S; Ţăruşi M; Dobreanu M
Clin Appl Thromb Hemost; 2017 Apr; 23(3):255-265. PubMed ID: 26873108
[TBL] [Abstract][Full Text] [Related]
7. Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation.
Harmsze A; van Werkum JW; Bouman HJ; Ruven HJ; Breet NJ; Ten Berg JM; Hackeng CM; Tjoeng MM; Klungel OH; de Boer A; Deneer VH
Pharmacogenet Genomics; 2010 Jan; 20(1):18-25. PubMed ID: 19934793
[TBL] [Abstract][Full Text] [Related]
8. Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel.
Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Cavallari U; Trabetti E; Sabaté M; Hernández R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Costa MA; Bass TA; Pignatti PF; Macaya C
Arterioscler Thromb Vasc Biol; 2006 Aug; 26(8):1895-900. PubMed ID: 16645157
[TBL] [Abstract][Full Text] [Related]
9. Platelet resistance to antiplatelet drugs.
Kumar A; Kao J
Recent Pat Cardiovasc Drug Discov; 2009 Jun; 4(2):98-108. PubMed ID: 19519552
[TBL] [Abstract][Full Text] [Related]
10. Clopidogrel and aspirin in cardiovascular medicine: responders or not--current best available evidence.
Tourmousoglou CE; Rokkas CK
Cardiovasc Hematol Agents Med Chem; 2008 Oct; 6(4):312-22. PubMed ID: 18855644
[TBL] [Abstract][Full Text] [Related]
11. Antiplatelet effect of aspirin in patients with coronary artery disease.
Grove EL
Dan Med J; 2012 Sep; 59(9):B4506. PubMed ID: 22951204
[TBL] [Abstract][Full Text] [Related]
12. Aspirin and clopidogrel resistance: methodological challenges and opportunities.
Gasparyan AY
Vasc Health Risk Manag; 2010 Mar; 6():109-12. PubMed ID: 20448796
[TBL] [Abstract][Full Text] [Related]
13. Platelet Function Testing in Patients with Acute Ischemic Stroke: An Observational Study.
Rosafio F; Lelli N; Mimmi S; Vandelli L; Bigliardi G; Dell'Acqua ML; Picchetto L; Pentore R; Ferraro D; Trenti T; Nichelli P; Zini A
J Stroke Cerebrovasc Dis; 2017 Aug; 26(8):1864-1873. PubMed ID: 28576652
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetics of the antiplatelet effect of aspirin.
Würtz M; Kristensen SD; Hvas AM; Grove EL
Curr Pharm Des; 2012; 18(33):5294-308. PubMed ID: 22724416
[TBL] [Abstract][Full Text] [Related]
15. Potential clinical utility of genetic and platelet function tests in patients on treatment with clopidogrel.
Cattaneo M
J Cardiovasc Med (Hagerstown); 2013 Dec; 14 Suppl 1():S16-21. PubMed ID: 24378837
[TBL] [Abstract][Full Text] [Related]
16. The CYP2C19*2 and CYP2C19*17 Polymorphisms play a Vital Role in Clopidogrel Responsiveness after Percutaneous Coronary Intervention: A Pharmacogenomics Study.
Saydam F; Değirmenci İ; Birdane A; Özdemir M; Ulus T; Özbayer C; Çolak E; Ata N; Güneş HV
Basic Clin Pharmacol Toxicol; 2017 Jul; 121(1):29-36. PubMed ID: 28135763
[TBL] [Abstract][Full Text] [Related]
17. Common variations in platelet glycoproteins: pharmacogenomic implications.
Quinn MJ; Topol EJ
Pharmacogenomics; 2001 Nov; 2(4):341-52. PubMed ID: 11722284
[TBL] [Abstract][Full Text] [Related]
18. Interindividual variability in the efficacy of oral antiplatelet drugs: definitions, mechanisms and clinical importance.
Würtz M; Grove EL
Curr Pharm Des; 2012; 18(33):5344-61. PubMed ID: 22724409
[TBL] [Abstract][Full Text] [Related]
19. Assessment, mechanisms, and clinical implication of variability in platelet response to aspirin and clopidogrel therapy.
Ben-Dor I; Kleiman NS; Lev E
Am J Cardiol; 2009 Jul; 104(2):227-33. PubMed ID: 19576352
[TBL] [Abstract][Full Text] [Related]
20. Resistance to antiplatelet therapy.
Guthikonda S; Lev EI; Kleiman NS
Curr Cardiol Rep; 2005 Jul; 7(4):242-8. PubMed ID: 15987620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
